Clinical-stage biotech developing novel cancer therapies
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Funding round Netherlands clinical-stage biotech iOnctura was granted €17.5M (€2.5M grant plus €15M equity) by the EIC Accelerator to advance its pancreatic cancer drug IOA-289. | $18.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.